Growth factors as treatments for stroke

Brain Repair After Stroke

Volumn , Issue , 2010, Pages 259-266

  Finklestein, Seth P ^a   Ren, JingMei ^a  

^a Biotrofix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927001055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511777547.024     Document Type: Chapter

References (64)

1. Ren JM, Finklestein SP. Growth factor treatment of stroke. Current Drug Targets – CNS Neurol Disord. 2005;39:121–5.
2. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann Neurol.2008;63:272–87.
3. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 2008;63:549–60.
4. Speliotes EK, Caday CG, Do T, et al. Increased expression of basic fibroblast growth factor (bFGF)following focal cerebral infarction in the rat. Mol BrainRes. 1996;39:31–42.
5. Finklestein SP, Kemmou A, Caday CG, et al. Basic fibroblast growth factor protects cerebrocorticalneurons against excitatory amino acid toxicity in vitro.Stroke. 1993;24(suppl I): I-141–143.
6. Walicke P, Cowan WM, Ueno N, et al. Fibroblast growth factor promotes survival of dissociatedhippocampal neurons and enhances neurite extension. Proc Natl Acad Sci USA. 1986;83:3012–6.
7. Koketsu N, Berlove DJ, Moskowitz MA, et al. Pretreatment with intraventricular basic fibroblastgrowth factor (bFGF) decreases infarct size following focal cerebral ischemia in rats. Ann Neurol.1994;35:451–7.
8. Fisher M, Meadows ME, Do T, et al. Delayed treatmentwith intravenous basic fibroblast growth factorreduces infarct size following permanent focal cerebralischemia in rats. J Cereb Blood Flow Metab. 1995;15:953–9.
9. Jiang N, Finklestein SP, Do T, et al. Delayed intravenous administration of basic fibroblast growth factor (bFGF)reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci. 1996;139:173–9.
10. Ren J, Finklestein SP. Time dependence of infarctreduction by intravenous basic fibroblast growth factor(bFGF) following focal cerebral ischemia in rats. Eur JPharmacol. 1997;327:11–6.
11. Rosenblatt S, Irikura K, Caday CG, et al. Basic fibroblast growth factor (bFGF) dilates rat pial arterioles. J CerebBlood Flow Metab. 1994;14: 70–4.
12. Huang Z, Chen K, Huang PL, et al. bFGF amelioratesfocal ischemic injury by blood flow-independentmechanisms in eNOS mutant mice. Am J Physiol.1996;272:H1401–05.
13. Ay I, Sugimori H, Finklestein SP. Intravenous basicfibroblast growth factor (bFGF) decreases DNAfragmentation and prevents downregulation of Bcl-2expression in the ischemic brain following middle cerebral artery occlusion in rats. Mol Brain Res.2001;87:71–80.
14. Watanabe T, Okuda Y, Nonoguchi N, et al. Postichemicintraventricular administration of FGF-2 expressingadenoviral vectors improves neurologic outcome andreduces infarct volume after transient focal cerebralischemia in rats. J Cereb Blood Flow Metab.2004;24:1205–13.
15. Liu Y, Lu JB, Ye ZR. Permeability of injured blood brainbarrier for exogenous bFGF and protection mechanismof bFGF in rat brain ischemia. Neuropathology. 2006;26:257–66.
16. Ma YP, Ma MM, Cheng SM, et al. Intranasal bFGFinduced progenitor cell proliferation andneuroprotection after transient focal cerebral ischemia.Neurosci Lett. 2002;30:93–7.
17. Kawamata T, Alexis NE, Dietrich WD, et al.Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebralinfarction in the rat. J Cereb Blood Flow Metab.1996;16:542–7.
18. Kawamata T, Dietrich WD, Schallert T, et al.Intracisternal basic fibroblast growth factor(bFGF) enhances functional recovery andupregulates the expression of a molecular marker of neuronal sprouting following focalcerebral infarction. Proc Natl Acad Sci USA. 1997;94:8179–84.
19. Berry D, Ren JM, Kwan C-P, et al. Dimeric fibroblast growth factor-2 enhances functional recovery afterfocal cerebral ischemia. Rest Neurol Neurosci.2005;23:.1–6.
20. Kawamata T, Ren JM, Cha CH, et al. Intracisternalantisense oligonucleotide to growth associated protein-43 (GAP-43) blocks the recovery-promoting effects of basic fibroblast growth factor (bFGF) after focal stroke.Exp Neurol. 1999;158:89–96.
21. Wada K, Sugimori H, Bhide PB, et al. Effect of basic fibroblast growth factor treatment on brain progenitorcells after permanent focal ischemia in rats. Stroke.2003;34:2722–8.
22. Leker RR, Soldner F, Velasco I, et al. Long-lasting regeneration after ischemia in the cerebral cortex.Stroke. 2007;38:153–61.
23. Wang ZL, Cheng SM, Ma MM, et al. Intranasally delivered bFGF enhances neurogenesis in adult ratsfollowing cerebral ischemia. Neurosci Lett.2008;28:30–5.
24. Won SJ, Xie L, Kim SH, et al. Influence of age on the response to fibroblast growth factor-2treatment in a rat model of stroke. Brain Res. 2006;1123:237–44.
25. Issa R, Alqteishat A, Mitsios N, et al. Expression of basic fibroblast growth factor mRNA and protein in thehuman brain following ischemic stroke. Angiogenesis. 2005;8:53–62.
26. Guo H, Huang L, Cheng M, et al. Serial measurement of serum basic fibroblast growth factor in patientswith acute cerebral infarction. Neurosci Lett. 2006;393:56–9.
27. Clark WM, Schim JD, Kasner SE, et al. Trafermin inacute ischemic stroke: Results of a phase II/IIIrandomized efficacy study. Neurology. 2000;54:A88.
28. Bogousslavsky J, Victor SJ, Salins EO, et al. Fiblast(Trafermin) in acute stroke: Results of the European– Australian Phase II/III safety and efficacy trial.Cerebrovasc Dis. 2002;14:239–51.
29. Sampath TK, Maliakal JC, Hauschka PV, et al.Recombinant human osteogenic protein-1 (hOP-1)induces new bone formation in vivo with a specificactivity comparable with mature bovine osteogenic protein and stimulates osteoblast proliferation anddifferentiation in vitro. J Biol Chem. 1992;267:20 352–62.
30. LeRoux P, Behar S, Higgins D, et al. OP-1 enhances dendritic growth from cerebral cortical neuronsin vitro. Exp Neurol. 1999;160:151–63.
31. Lin SZ, Hoffer BJ, Kaplan P, et al. Osteogenic protein-1protects against cerebral infarction induced by MCAligation in adult rats. Stroke. 1999;30:126–33.
32. Kawamata T, Ren J, Chan TCK, et al. Intracisternalosteogenic protein-1 enhances functional recoveryfollowing focal stroke. NeuroReport. 1998;9:1441–5.
33. Ren J, Kaplan PL, Charette MF, et al. Time window ofintracisternal osteogenic protein-1 in enhancingfunctional recovery after stroke. Neuropharmacology.2000;39:860–5.
34. Liu Y, Belayev L, Zhao W, et al. The effect of bonemorphogenetic protein-7 (BMP-7) on functionalrecovery, local cerebral glucose utilization and bloodflow after transient focal cerebral ischemia in rats. Brain Res. 2001;905:81–90.
35. Chang CF, Lin SZ, Chiang YH, et al. Intravenous administration of bone morphogenetic protein-7 afterischemia improves motor function in stroke rats.Stroke. 2003;34:558–64.
36. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and poststrokerecovery. J Neurosci. 2006;26:1269–74.
37. Carmichael ST. Cellular and molecular mechanisms ofneural repair after stroke: Making waves. Ann Neurol. 2006;59:735–42.
38. Brines ML, Ghezzi P, Keenan S, et al. Erythropoeitincrosses the blood–brain barrier to protect againstexperimental brain injury. Proc Natl Acad Sci USA. 2000;97:10 526–31.
39. Siren AL, Fratelli M, Brines M, et al. Erythropoietinprevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044–9.
40. Yu YP, Xu QQ, Zhang Q, et al. Intranasal recombinanthuman erythropoietin protects rats against focalcerebral ischemia. Neurosci Lett. 2005; 387: 5–10.
41. Li Y, Lu Z, Keogh CL, et al. Erythropoietin-inducedneurovascular protection, angiogenesis, and cerebralblood flow restoration after focal ischemia in mice.J Cereb Blood Flow Metab. 2007;27:1043–54.
42. Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythropoietin or carbamylatederythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebralischemia. Br J Pharmacol. 2007;151:1141–2.
43. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis andangiogenesis and improves neurological function in rats. Stroke. 2004;35:1732–7.
44. Kolb B, Morshead C, Gonzalez C, et al. Growth factorstimulatedgeneration of new cortical tissue andfunctional recovery after stroke damage to the motorcortex of rats. J Cereb Blood Flow Metab. 2007;27:983–97.
45. Belayev L, Khoutorova L, Zhao KL, et al. A novel neurotrophic therapeutic strategy for experimental stroke. Brain Res. 2009;1280:117–23.
46. Ehrenreich H, Hasselblatt M, Dembowski C, et al.Erythropoietin therapy for acute stroke is both safe andbeneficial. Mol Med. 2002;8:495–505.
47. Schabitz WR, Kollmar R, Schwaninger M, et al.Neuroprotective effect of granulocyte colonystimulatingfactor after focal cerebral ischemia. Stroke. 2003;34:745–51.
48. Gibson CL, Bath PM, Murphy SP. G-CSF reduces infarct volume and improves functional outcome aftertransient focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2005;25:431–9.
49. Lee ST, Chu K, Jung KH, et al. Granulocyte colonystimulatingfactor enhances angiogenesis after focalcerebral ischemia. Brain Res. 2005;1058:120–8.
50. Schneider A, Kruger C, Steigleder T, et al. The hematopoietic growth factor G-CSF is aneuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest.2005;115:2083–98.
51. Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant humangranulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab.2006;26:402–13.
52. Solaroglu I, Tsubokawa T, Cahill J, et al. Anti-apoptotic effect of granulocyte colony-stimulating factor afterfocal cerebral ischemia in the rat. Neuroscience. 2006;143:965–74.
53. Yanqing Z, Yu-Min L, Jian Q, et al. Fibronectin and neuroprotective effect of granulocyte colony- stimulating factor in focal cerebral ischemia. Brain Res. 2006;1098:161–9.
54. Sehara Y, Hayashi T, Degushi K, et al. Decreased focal inflammatory response by G-CSF may improvestroke outcome following transient middle cerebral artery occlusion in rats. J Neurosci Res.2007;85:2167–74.
55. Gibson CL, Jones NC, Prior MJ, et al. G-CSF suppresses edema formation and reducesinterleukin-1beta expression after cerebral ischemiain mice. J Neuropathol Exp Neurol.2005;64:763–9.
56. Zhao LR, Singhal S, Duan WM, et al. Brain repair byhematopoietic growth factors in a rat model of stroke.Stroke. 2007;38:2584–91.
57. Six I, Gassan G, Mura E, et al. Beneficial effect ofpharmacological mobilization of bone marrow inexperimental cerebral ischemia. Eur J Pharmacol. 2003;458:327–8.
58. Shyu WC, Lin SZ, Yang HI, et al. Functional recovery ofstroke rats induced by granulocyte colony-stimulatingfactor-stimulated stem cells. Circulation. 2004;110:1847–54.
59. Schneider A, Wysocki R, Pitzer C, et al. An extended window of oppoortunity for G-CSF treatment incerebral ischemia. BMC Biol. 2006;4:36.
60. Minnerup J, Heidrich J, Wellmann J, et al. Metaanalysisof the efficacy of granulocyte-colonystimulating factor in animal models of focal cerebralischemia. Stroke. 2008;39:1855–61.
61. Shyu WC, Lin SZ, Lee CC, et al. Granulocyte colonystimulationgfactor for acute ischemic stroke: Arandomized controlled trial. CMAJ. 2006;174:927–33.
62. Sprigg N, Bath PM, Zhao L, et al. Granulocyte-colonystimulatingfactor mobilizes bone marrow stem cells inpatients with subacute ischemic stroke. The Stem ell Trial of Recovery EnhanceMent After Stroke (STEMS)pilot randomized, controlled trial (ISRCTN 16784092).Stroke. 2006;37:2979–83.
63. Moore TI, Killiany RJ, Finklestein S, et al. Non-human primate model of motor recovery after cortical stroke.Soc Neurosci Abstr. 2003:414.1.
64. Cramer SC, Koroshetz WJ, Finklestein SP. The case formodality-specific outcome measures in clinical trials ofstroke recovery-promoting agents. Stroke. 2007;38:1393–5.